ClinicalTrials.gg
CompletedNCT01753323Updated Jun 7, 2018Results posted

Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

A Phase 2 interventional study of KAF156 in Malaria, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in 2 countries. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-06-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Non-randomized
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Malaria by Novartis — 3 open to participants now, 3 under way, none of them phase 3. Malaria · Novartis.

Enrollment
13th of 21
43 · median 57
Started
2013
the only one that year
Phase 2
6 of 24
1 open now
Registered
10th of 24
by date

Among the 24 studies in Malaria by Novartis, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2013, is one of 6 in phase 2, and was the 10th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

3 of the 24 studies in Malaria by Novartis are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Malaria by Novartis, or all of them as a file.
02

Study summary

This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400 mg/day (Part 1) and single dosing with KAF156 at 800mg (Part 2)

03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • acute malaria, KAF156
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Male and female patients aged 20 to 60 years;Presence of mono-infection of P. falciparum or P. vivax; Weight between 40 kg to 90 kg.

Exclusion criteria

Exclusion Criteria:

  • Patients with signs and symptoms of severe/complicated malaria
  • Infection with more than one parasite species
  • Women of ; pregnant or nursing women
  • Those who have taken any anti-malarial treatment in the preceding 14 days or other drugs within 30 days or 5 half-lives
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Part 1 - Cohort 1: P. vivax: KAF156 400mg QD

    Participants with Plasmodium vivax malaria received KAF156 400 mg once a day for three days.

    Drug: KAF156

  • Experimental
    Part 1 - Cohort 2: P. falciparum: KAF156 400mg QD

    Participants with Plasmodium falciparum malaria received KAF156 400mg once a day for three days.

    Drug: KAF156

  • Experimental
    Part 2 - Cohort 3: P. falciparum: KAF156 800mg single dose

    Participants with Plasmodium falciparum malaria received a single dose of KAF156 800mg.

    Drug: KAF156

Interventions

  • DrugKAF156

    KAF156 was supplied as tablets for oral use.

06

What researchers measure

Primary outcomes

  1. Time to Parasite Clearance

    Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and blood density assessments.

    Time frame: Day 5

  2. 28-day Cure Rate - Part 2

    28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment.

    Time frame: Day 28

Secondary outcomes

  1. Area Under the Curve (AUC)0-24h - Part 1

    AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose was taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Days 1 and 3

  2. Maximum Concentration (Cmax) - Part 1

    Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Days 1 and 3

  3. Time to Maximum Concentration (Tmax) - Part 1

    Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Days 1 and 3

  4. Area Under the Curve (AUC)Last - Part 1

    AUClast was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 3

  5. Area Under the Curve (AUC)Inf - Part 1

    AUCinf was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 3

  6. Half-life (T1/2) - Part 1

    T1/2 was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 3

  7. Clearance (CL/F ) - Part 1

    CL/F was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 3

  8. Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1

    Vz/F was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 3

  9. Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1

    Racc was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 3

  10. AUC0-24h - Part 2

    AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.

    Time frame: Day 1

  11. AUC0-48h - Part 2

    AUC0-48h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 1

  12. AUClast - Part 2

    AUClast was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose

    Time frame: Day 1

  13. AUCinf - Part 2

    AUCinf was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose

    Time frame: Day 1

  14. Cmax - Part 2

    Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.

    Time frame: Day 1

  15. Tmax - Part 2

    Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.

    Time frame: Day 1

  16. T1/2 - Part 2

    T1/2 was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 1

  17. CL/F - Part 2

    CL/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 1

  18. Vz/F - Part 2

    Vz/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

    Time frame: Day 1

07

Results

Posted Aug 19, 2015

Participant flow

Participant flow — Overall Study
MilestonePart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QDPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
Started111022
Pharmacodynamic (pd) set101021
Pharmacokinetic(pk) set101021
Safety set111022
Intent-to-treat analysis set111022
Completed101013
Not completed109
Withdrew: Lack of efficacy008
Withdrew: Protocol deviation100
Withdrew: Adverse event001

Outcome measures

PrimaryTime to Parasite Clearance

Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and blood density assessments.

Time frame:
Day 5
Reported as:
Median · Hours
Time to Parasite Clearance
HoursPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QDPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
Time to Parasite Clearance23.63 (16.00 to 30.02)44.97 (36.25 to 47.98)48.75 (42.00 to 53.95)
Primary28-day Cure Rate - Part 2

28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment.

Time frame:
Day 28
Reported as:
Number · Percentage of participants
28-day Cure Rate - Part 2
Percentage of participantsPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
28-day Cure Rate - Part 263.6
SecondaryArea Under the Curve (AUC)0-24h - Part 1

AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose was taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Days 1 and 3
Reported as:
Mean · (hr*ng/mL)
Area Under the Curve (AUC)0-24h - Part 1
(hr*ng/mL)Part 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Day 19470 ± 214010100 ± 2440
Day 320200 ± 373021700 ± 6630
SecondaryMaximum Concentration (Cmax) - Part 1

Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Days 1 and 3
Reported as:
Mean · ng/mL
Maximum Concentration (Cmax) - Part 1
ng/mLPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Day 1795 ± 182856 ± 158
Day 31440 ± 2991620 ± 384
SecondaryTime to Maximum Concentration (Tmax) - Part 1

Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose. The 24h sampling of first post dose should be taken before the second dose. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Days 1 and 3
Reported as:
Median · hour
Time to Maximum Concentration (Tmax) - Part 1
hourPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Day 13.00 (2.00 to 6.00)3.00 (1.00 to 4.03)
Day 33.00 (2.00 to 5.98)2.52 (2.00 to 3.02)
SecondaryArea Under the Curve (AUC)Last - Part 1

AUClast was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 3
Reported as:
Mean · hr*ng/mL
Area Under the Curve (AUC)Last - Part 1
hr*ng/mLPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Area Under the Curve (AUC)Last - Part 155800 ± 1280054300 ± 22500
SecondaryArea Under the Curve (AUC)Inf - Part 1

AUCinf was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 3
Reported as:
Mean · hr*ng/mL
Area Under the Curve (AUC)Inf - Part 1
hr*ng/mLPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Area Under the Curve (AUC)Inf - Part 158300 ± 1450056700 ± 24800
SecondaryHalf-life (T1/2) - Part 1

T1/2 was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 3
Reported as:
Mean · hr
Half-life (T1/2) - Part 1
hrPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Half-life (T1/2) - Part 139.0 ± 7.4040.8 ± 8.37
SecondaryClearance (CL/F ) - Part 1

CL/F was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 3
Reported as:
Mean · L/hr
Clearance (CL/F ) - Part 1
L/hrPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Clearance (CL/F ) - Part 120.4 ± 4.0419.7 ± 5.12
SecondaryApparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1

Vz/F was analyzed using parent drug in plasma samples. On Day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 3
Reported as:
Mean · Liters
Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 1
LitersPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Apparent Volume of Distribution During the Terminal Elimination Phase Following Extravascular Administration (Vz/F) - Part 11150 ± 2861140 ± 288
SecondaryAccumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1

Racc was analyzed using parent drug in plasma samples. On day 3, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 3
Reported as:
Mean · ratio
Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 1
ratioPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QD
Accumulation Ratio (Racc) (=AUC0-24h, day3/AUC0-24h, day1) - Part 12.16 ± 0.2562.15 ± 0.384
SecondaryAUC0-24h - Part 2

AUC0-24h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.

Time frame:
Day 1
Reported as:
Mean · hr*ng/mL
AUC0-24h - Part 2
hr*ng/mLPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
AUC0-24h - Part 221700 ± 5680
SecondaryAUC0-48h - Part 2

AUC0-48h was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 1
Reported as:
Mean · hr*ng/mL
AUC0-48h - Part 2
hr*ng/mLPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
AUC0-48h - Part 233600 ± 9150
SecondaryAUClast - Part 2

AUClast was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose

Time frame:
Day 1
Reported as:
Mean · hr*ng/mL
AUClast - Part 2
hr*ng/mLPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
AUClast - Part 254900 ± 16600
SecondaryAUCinf - Part 2

AUCinf was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose

Time frame:
Day 1
Reported as:
Mean · hr*ng/mL
AUCinf - Part 2
hr*ng/mLPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
AUCinf - Part 258300 ± 18600
SecondaryCmax - Part 2

Cmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.

Time frame:
Day 1
Reported as:
Mean · ng/mL
Cmax - Part 2
ng/mLPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
Cmax - Part 21800 ± 404
SecondaryTmax - Part 2

Tmax was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 24 hours post dose.

Time frame:
Day 1
Reported as:
Median · hours
Tmax - Part 2
hoursPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
Tmax - Part 23.52 (2.00 to 11.6)
SecondaryT1/2 - Part 2

T1/2 was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 1
Reported as:
Mean · hours
T1/2 - Part 2
hoursPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
T1/2 - Part 248.7 ± 7.85
SecondaryCL/F - Part 2

CL/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 1
Reported as:
Mean · L/hr
CL/F - Part 2
L/hrPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
CL/F - Part 215.1 ± 4.85
SecondaryVz/F - Part 2

Vz/F was analyzed using parent drug in plasma samples. On Day 1, samples were taken at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, and 192 hours post dose.

Time frame:
Day 1
Reported as:
Mean · Liters
Vz/F - Part 2
LitersPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
Vz/F - Part 21030 ± 264

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 - Cohort 1: P. Vivax: KAF156 400mg QD—0/11 (0%)5/11 (45.5%)
Part 1 - Cohort 2: P. Falciparum: KAF156 400mg QD—0/10 (0%)8/10 (80%)
Part 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose—0/22 (0%)22/22 (100%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPart 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QDPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single Dose
Sinus bradycardiaCardiac disorders1/113/1014/22
ThrombocytopeniaBlood and lymphatic system disorders0/111/1013/22
HypokalaemiaMetabolism and nutrition disorders0/111/1011/22
AnaemiaBlood and lymphatic system disorders0/111/107/22
VomitingGastrointestinal disorders0/111/106/22
Alanine aminotransferase increasedInvestigations1/111/105/22
Decreased appetiteMetabolism and nutrition disorders0/111/105/22
Abdominal painGastrointestinal disorders0/112/101/22
NeutropeniaBlood and lymphatic system disorders0/110/104/22
DiarrhoeaGastrointestinal disorders0/110/104/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Part 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QDPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single DoseTotal
Mean28.1 ± 8.4236.7 ± 10.9028.9 ± 7.0031.2 ± 8.77
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part 1 - Cohort 1: P. Vivax: KAF156 400mg QDPart 1 - Cohort 2: P. Falciparum: KAF156 400mg QDPart 2 - Cohort 3: P. Falciparum: KAF156 800mg Single DoseTotal
Number11102243
08

Study locations

5 sites
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Srisaket, 33140, Thailand
  • Novartis Investigative Site
    Tak, 63110, Thailand
  • Novartis Investigative Site
    Tak, 63140, Thailand
  • Novartis Investigative Site
    Hanoi, 10000, Vietnam
09

References and documents

Publications

  • White NJ, Duong TT, Uthaisin C, Nosten F, Phyo AP, Hanboonkunupakarn B, Pukrittayakamee S, Jittamala P, Chuthasmit K, Cheung MS, Feng Y, Li R, Magnusson B, Sultan M, Wieser D, Xun X, Zhao R, Diagana TT, Pertel P, Leong FJ. Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. N Engl J Med. 2016 Sep 22;375(12):1152-60. doi: 10.1056/NEJMoa1602250. PubMed 27653565 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Aug 2014 and a completion of Aug 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2012
First posted
Dec 20, 2012
Start
Mar 2013
Primary completionActual
Aug 2014
CompletionActual
Aug 2014
Results first posted
Aug 19, 2015
Last update
Jun 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01753323
Responsible party
Sponsor
First posted
Dec 20, 2012
Start date
Mar 2013
Primary completion
Aug 2014
Completion
Aug 2014
Results posted
Aug 19, 2015
Last update
Jun 7, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ganaplacide

Start the discussion